Makino, Tomoki
Miyata, Hiroshi
Yasuda, Takushi http://orcid.org/0000-0003-4025-8113
Kitagawa, Yuko
Muro, Kei
Park, Jae-Hyun
Hikichi, Tetsuro
Hasegawa, Takahiro
Igarashi, Kenji
Iguchi, Motofumi
Masaoka, Yasuhide
Yano, Masahiko
Doki, Yuichiro
Funding for this research was provided by:
OncoTherapy Science Inc.
Shionogi
Article History
Received: 30 April 2024
Accepted: 2 July 2024
First Online: 11 July 2024
Declarations
:
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
: TM reports honoraria from Ono Pharmaceutical, MSD, and research funding from Takeda Pharmaceutical. YK reports grants to his institution from Chugai Pharmaceutical, Taiho Pharmaceutical, Asahi Kasei Pharma, Otsuka Pharmaceutical, Tsumura, Kaken Pharmaceutical, Sumitomo Pharma, Eisai, Otsuka Pharmaceutical Factory, Kyowa Kirin, Takeda Pharmaceutical, Teijin Pharma, and Kowa; and personal fee from Asahi Kasei Pharma, Astra Zeneca, Ethicon, Ono Pharmaceutical, Otsuka Pharmaceutical Factory, Olympus, Cardinal Health, Shionogi & Co., Ltd., Taiho Pharmaceutical, Chugai Pharmaceutical, Bristol-Myers Squibb, MSD, Smith & Nephew, Kaken Pharmaceutical, Aska Pharmaceutical, Miyarisan Pharmaceutical, Toray Industries, Daiichi Sankyo, Chugai Foundation for Innovation Drug Discovery Science, Nippon Kayaku, EA Pharma, Intuitive Surgical, Takeda Pharmaceutical, Sysmex, Tsumura, AI Medical Service, Kowa, and Eisai; and Joint Research Laboratory for Development and Education of Innovative Medical Technology for Sysmex and Medicaroid; and Editor in Chief of Annals of Gastroenterological Surgery issued by The Japanese Society of Gastroenterological Surgery. KM reports honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Eli Lilly, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical and MSD; and research funding from PRA Health Science, Astellas, Novartis Pharma, Amgen, Sanofi, Taiho Pharmaceutical, MSD, Chugai Pharmaceutical and Paraxel International. YD reports that his institution received a research grant from Shionogi & Co., Ltd outside of this clinical study. JP is an employee of OncoTherapy Science Inc. THi is an employee of OncoTherapy Science, Inc. and an assigned employee of Cancer Precision Medicine, Inc, and has stock options of OncoTherapy Science, Inc.; and patent pending (WO 2022/149295). THa is an employee of Shionogi & Co., Ltd., and has stocks of Shionogi & Co., Ltd. YM was an employee of Shionogi & Co., Ltd. when the study was conducted, and has minor stocks of Shionogi & Co., Ltd.; and reports participation on Data safety Monitoring Board and Advisory Board that Shionogi & Co., Ltd. held. KI, and MI were also employees of Shionogi & Co., Ltd. when the study was conducted. All other authors declare that they have no conflict of interest.
: Informed consent or substitute for it was obtained from all patients for being included in the study.